Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis

Dinesh Khanna, Daniel E. Furst, Weng Kee Wong, Joel Tsevat, Philip J. Clements, Grace S. Park, Arnold Postlethwaite, Mansoor Ahmed, Shaari Ginsburg, Ron D. Hays

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: To evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis (SSc). Subjects: We used data from two clinical studies to analyze the SF-6D in patients with SSc: Study 1 was a cross-sectional observational study (N = 107) designed to assess three direct preference measures-the rating scale, time trade-off, and standard gamble (SG) in patients with diffuse SSc and limited SSc, and Study 2 was a 12-month randomized, placebo-controlled, clinical trial (N = 168) assessing oral bovine collagen versus placebo in diffuse SSc. Methods: We assessed the test-retest reliability of the SF-6D in Study 2 over a mean (SD) 4.8 (3.0)-week interval and the agreement between the SF-6D and direct preference measures in Study 1 using intraclass correlations (ICC). The MID was estimated using three different anchors-the SF-36 change in health item (patients who answered "somewhat better" formed the MID group), the Health Assessment Questionnaire-Disability Index (HAQ-DI; change of ≥0.14 and ≥0.22) and the skin score (change of ≥5.3). Results: The mean (SD) SF-6D scores were 0.61 (0.12) in Study 1 and 0.64 (0.13) in Study 2. Test-retest reliability for the SF-6D was high (ICC = 0.82 [95% CI: 0.76, 0.87]). Agreement between the SF-6D and three direct preferences measures was poor to moderate (0.16-0.52). The MID estimate for the SF-6D using the change in SF-36 item -0.012 and this level of change was similar to the no change group. The mean MID estimate for the SF-6D improvement using the HAQ-DI and skin score as anchors was 0.035 (effect size of 0.27). Conclusion: This is the first study to assess the SF-6D in SSc. The SF-6D is reliable and valid in patients with SSc. We provide MID estimates that can aid in calculating sample size for clinical trials involving patients with diffuse SSc.

Original languageEnglish (US)
Pages (from-to)1083-1092
Number of pages10
JournalQuality of Life Research
Volume16
Issue number6
DOIs
StatePublished - Aug 1 2007

Fingerprint

Systemic Scleroderma
Reproducibility of Results
ametantrone
Diffuse Scleroderma
Placebos
Skin
Health
Sample Size
Observational Studies
Collagen
Randomized Controlled Trials
Cross-Sectional Studies
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Khanna, D., Furst, D. E., Wong, W. K., Tsevat, J., Clements, P. J., Park, G. S., ... Hays, R. D. (2007). Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Quality of Life Research, 16(6), 1083-1092. https://doi.org/10.1007/s11136-007-9207-3

Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. / Khanna, Dinesh; Furst, Daniel E.; Wong, Weng Kee; Tsevat, Joel; Clements, Philip J.; Park, Grace S.; Postlethwaite, Arnold; Ahmed, Mansoor; Ginsburg, Shaari; Hays, Ron D.

In: Quality of Life Research, Vol. 16, No. 6, 01.08.2007, p. 1083-1092.

Research output: Contribution to journalArticle

Khanna, D, Furst, DE, Wong, WK, Tsevat, J, Clements, PJ, Park, GS, Postlethwaite, A, Ahmed, M, Ginsburg, S & Hays, RD 2007, 'Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis', Quality of Life Research, vol. 16, no. 6, pp. 1083-1092. https://doi.org/10.1007/s11136-007-9207-3
Khanna, Dinesh ; Furst, Daniel E. ; Wong, Weng Kee ; Tsevat, Joel ; Clements, Philip J. ; Park, Grace S. ; Postlethwaite, Arnold ; Ahmed, Mansoor ; Ginsburg, Shaari ; Hays, Ron D. / Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. In: Quality of Life Research. 2007 ; Vol. 16, No. 6. pp. 1083-1092.
@article{b0ef723c417041c19de93e2a44541055,
title = "Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis",
abstract = "Objectives: To evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis (SSc). Subjects: We used data from two clinical studies to analyze the SF-6D in patients with SSc: Study 1 was a cross-sectional observational study (N = 107) designed to assess three direct preference measures-the rating scale, time trade-off, and standard gamble (SG) in patients with diffuse SSc and limited SSc, and Study 2 was a 12-month randomized, placebo-controlled, clinical trial (N = 168) assessing oral bovine collagen versus placebo in diffuse SSc. Methods: We assessed the test-retest reliability of the SF-6D in Study 2 over a mean (SD) 4.8 (3.0)-week interval and the agreement between the SF-6D and direct preference measures in Study 1 using intraclass correlations (ICC). The MID was estimated using three different anchors-the SF-36 change in health item (patients who answered {"}somewhat better{"} formed the MID group), the Health Assessment Questionnaire-Disability Index (HAQ-DI; change of ≥0.14 and ≥0.22) and the skin score (change of ≥5.3). Results: The mean (SD) SF-6D scores were 0.61 (0.12) in Study 1 and 0.64 (0.13) in Study 2. Test-retest reliability for the SF-6D was high (ICC = 0.82 [95{\%} CI: 0.76, 0.87]). Agreement between the SF-6D and three direct preferences measures was poor to moderate (0.16-0.52). The MID estimate for the SF-6D using the change in SF-36 item -0.012 and this level of change was similar to the no change group. The mean MID estimate for the SF-6D improvement using the HAQ-DI and skin score as anchors was 0.035 (effect size of 0.27). Conclusion: This is the first study to assess the SF-6D in SSc. The SF-6D is reliable and valid in patients with SSc. We provide MID estimates that can aid in calculating sample size for clinical trials involving patients with diffuse SSc.",
author = "Dinesh Khanna and Furst, {Daniel E.} and Wong, {Weng Kee} and Joel Tsevat and Clements, {Philip J.} and Park, {Grace S.} and Arnold Postlethwaite and Mansoor Ahmed and Shaari Ginsburg and Hays, {Ron D.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1007/s11136-007-9207-3",
language = "English (US)",
volume = "16",
pages = "1083--1092",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis

AU - Khanna, Dinesh

AU - Furst, Daniel E.

AU - Wong, Weng Kee

AU - Tsevat, Joel

AU - Clements, Philip J.

AU - Park, Grace S.

AU - Postlethwaite, Arnold

AU - Ahmed, Mansoor

AU - Ginsburg, Shaari

AU - Hays, Ron D.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Objectives: To evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis (SSc). Subjects: We used data from two clinical studies to analyze the SF-6D in patients with SSc: Study 1 was a cross-sectional observational study (N = 107) designed to assess three direct preference measures-the rating scale, time trade-off, and standard gamble (SG) in patients with diffuse SSc and limited SSc, and Study 2 was a 12-month randomized, placebo-controlled, clinical trial (N = 168) assessing oral bovine collagen versus placebo in diffuse SSc. Methods: We assessed the test-retest reliability of the SF-6D in Study 2 over a mean (SD) 4.8 (3.0)-week interval and the agreement between the SF-6D and direct preference measures in Study 1 using intraclass correlations (ICC). The MID was estimated using three different anchors-the SF-36 change in health item (patients who answered "somewhat better" formed the MID group), the Health Assessment Questionnaire-Disability Index (HAQ-DI; change of ≥0.14 and ≥0.22) and the skin score (change of ≥5.3). Results: The mean (SD) SF-6D scores were 0.61 (0.12) in Study 1 and 0.64 (0.13) in Study 2. Test-retest reliability for the SF-6D was high (ICC = 0.82 [95% CI: 0.76, 0.87]). Agreement between the SF-6D and three direct preferences measures was poor to moderate (0.16-0.52). The MID estimate for the SF-6D using the change in SF-36 item -0.012 and this level of change was similar to the no change group. The mean MID estimate for the SF-6D improvement using the HAQ-DI and skin score as anchors was 0.035 (effect size of 0.27). Conclusion: This is the first study to assess the SF-6D in SSc. The SF-6D is reliable and valid in patients with SSc. We provide MID estimates that can aid in calculating sample size for clinical trials involving patients with diffuse SSc.

AB - Objectives: To evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis (SSc). Subjects: We used data from two clinical studies to analyze the SF-6D in patients with SSc: Study 1 was a cross-sectional observational study (N = 107) designed to assess three direct preference measures-the rating scale, time trade-off, and standard gamble (SG) in patients with diffuse SSc and limited SSc, and Study 2 was a 12-month randomized, placebo-controlled, clinical trial (N = 168) assessing oral bovine collagen versus placebo in diffuse SSc. Methods: We assessed the test-retest reliability of the SF-6D in Study 2 over a mean (SD) 4.8 (3.0)-week interval and the agreement between the SF-6D and direct preference measures in Study 1 using intraclass correlations (ICC). The MID was estimated using three different anchors-the SF-36 change in health item (patients who answered "somewhat better" formed the MID group), the Health Assessment Questionnaire-Disability Index (HAQ-DI; change of ≥0.14 and ≥0.22) and the skin score (change of ≥5.3). Results: The mean (SD) SF-6D scores were 0.61 (0.12) in Study 1 and 0.64 (0.13) in Study 2. Test-retest reliability for the SF-6D was high (ICC = 0.82 [95% CI: 0.76, 0.87]). Agreement between the SF-6D and three direct preferences measures was poor to moderate (0.16-0.52). The MID estimate for the SF-6D using the change in SF-36 item -0.012 and this level of change was similar to the no change group. The mean MID estimate for the SF-6D improvement using the HAQ-DI and skin score as anchors was 0.035 (effect size of 0.27). Conclusion: This is the first study to assess the SF-6D in SSc. The SF-6D is reliable and valid in patients with SSc. We provide MID estimates that can aid in calculating sample size for clinical trials involving patients with diffuse SSc.

UR - http://www.scopus.com/inward/record.url?scp=34547408278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547408278&partnerID=8YFLogxK

U2 - 10.1007/s11136-007-9207-3

DO - 10.1007/s11136-007-9207-3

M3 - Article

C2 - 17404896

AN - SCOPUS:34547408278

VL - 16

SP - 1083

EP - 1092

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 6

ER -